ARTICLE | Company News

Asterand Bioscience, ReproCell deal

October 20, 2014 7:00 AM UTC

ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc., now known as Asterand Biosciences Inc., for about $8.5 million in cash. Asterand will now focus on its human tissue-based research services for drug and biomarker discovery and development. ReproCell gained all assets of the business, plus all employees located at Asterand's facility in Cambridge. ReproCell said the deal expands its iPS product lineup and strengthens its sales and marketing in the U.S. ...